简要报告卡铂、每周紫杉醇和 Pembrolizumab 用于 PD-L1 < 50% 的晚期非小细胞肺癌老年患者：真实世界数据。

IF 3.3 3区医学 Q2 ONCOLOGY Clinical lung cancer Pub Date : 2024-11-01 Epub Date: 2024-05-18 DOI:10.1016/j.cllc.2024.05.005

{"title":"简要报告卡铂、每周紫杉醇和 Pembrolizumab 用于 PD-L1 < 50% 的晚期非小细胞肺癌老年患者：真实世界数据。","authors":"","doi":"10.1016/j.cllc.2024.05.005","DOIUrl":null,"url":null,"abstract":"<div><div><ul><li><span>•</span><span><div><span>Carboplatin<span>, weekly Paclitaxel (CwP) and </span></span>Pembrolizumab<span> is feasible in patients aged ≥70 with stage IV NSCLC and PD-L1 < 50%</span></div></span></li><li><span>•</span><span><div>Progression-Free Survival and Overall Survival are improved with addition of Pembrolizumab to CwP in this population</div></span></li><li><span>•</span><span><div>Toxicity profile is consistent with that of other populations, although with a higher frequency of anemia</div></span></li><li><span>•</span><span><div>Addition of Pembrolizumab to CwP should be considered in selected patients aged ≥ 70 with stage IV NSCLC and PD-L1 < 50%</div></span></li></ul></div></div>","PeriodicalId":10490,"journal":{"name":"Clinical lung cancer","volume":"25 7","pages":"Pages e323-e329"},"PeriodicalIF":3.3000,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Brief Report: Carboplatin, Weekly Paclitaxel and Pembrolizumab in Elderly Patients for Advanced Non-Small Cell Lung Cancer With PD-L1 < 50%: Real-World Data.\",\"authors\":\"\",\"doi\":\"10.1016/j.cllc.2024.05.005\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><div><ul><li><span>•</span><span><div><span>Carboplatin<span>, weekly Paclitaxel (CwP) and </span></span>Pembrolizumab<span> is feasible in patients aged ≥70 with stage IV NSCLC and PD-L1 < 50%</span></div></span></li><li><span>•</span><span><div>Progression-Free Survival and Overall Survival are improved with addition of Pembrolizumab to CwP in this population</div></span></li><li><span>•</span><span><div>Toxicity profile is consistent with that of other populations, although with a higher frequency of anemia</div></span></li><li><span>•</span><span><div>Addition of Pembrolizumab to CwP should be considered in selected patients aged ≥ 70 with stage IV NSCLC and PD-L1 < 50%</div></span></li></ul></div></div>\",\"PeriodicalId\":10490,\"journal\":{\"name\":\"Clinical lung cancer\",\"volume\":\"25 7\",\"pages\":\"Pages e323-e329\"},\"PeriodicalIF\":3.3000,\"publicationDate\":\"2024-11-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical lung cancer\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1525730424000846\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/5/18 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q2\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical lung cancer","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1525730424000846","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/5/18 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

-卡铂、每周紫杉醇（CwP）和 Pembrolizumab 可用于年龄≥70 岁的 IV 期 NSCLC 患者，且 PD-L1 <；Pembrolizumab在CwP中的应用提高了无进展生存期和总生存期-毒性特征与其他人群一致，但贫血发生率较高-在CwP中添加Pembrolizumab，应考虑用于年龄≥70岁的IV期NSCLC和PD-L1 <50%的患者。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

Brief Report: Carboplatin, Weekly Paclitaxel and Pembrolizumab in Elderly Patients for Advanced Non-Small Cell Lung Cancer With PD-L1 < 50%: Real-World Data.

•
Carboplatin, weekly Paclitaxel (CwP) and Pembrolizumab is feasible in patients aged ≥70 with stage IV NSCLC and PD-L1 < 50%
•
Progression-Free Survival and Overall Survival are improved with addition of Pembrolizumab to CwP in this population
•
Toxicity profile is consistent with that of other populations, although with a higher frequency of anemia
•
Addition of Pembrolizumab to CwP should be considered in selected patients aged ≥ 70 with stage IV NSCLC and PD-L1 < 50%

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Clinical lung cancer 医学-肿瘤学

CiteScore

7.00

自引率

2.80%

发文量

159

审稿时长

24 days

期刊介绍： Clinical Lung Cancer is a peer-reviewed bimonthly journal that publishes original articles describing various aspects of clinical and translational research of lung cancer. Clinical Lung Cancer is devoted to articles on detection, diagnosis, prevention, and treatment of lung cancer. The main emphasis is on recent scientific developments in all areas related to lung cancer. Specific areas of interest include clinical research and mechanistic approaches; drug sensitivity and resistance; gene and antisense therapy; pathology, markers, and prognostic indicators; chemoprevention strategies; multimodality therapy; and integration of various approaches.